AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
LEO Pharma helps people achieve healthy skin. By offering care solutions to patients in more than 100 countries globally, LEO Pharma supports people in managing their skin conditions. Founded in 1908 and owned by the LEO Foundation, the healthcare company has devoted decades of research and development to delivering products and solutions to people with skin conditions. LEO Pharma is headquartered in Denmark and employs around 4,800 people worldwide.
"Antibodies have changed the treatment of anti-inflammatory skin diseases in the last decade and shown superior efficacy to other systemic treatments. As a result, moving into antibody development is a natural step for LEO Pharma. We selected arGEN-X as our partner because of their strong technology platform, their proven track record of progressing projects to clinical testing and their strong competencies in antibody development. We have initiated our collaboration very efficiently and are exploiting synergies between us - combining arGEN-X’s knowledge of antibody technology with our expertise in skin diseases."
Thorsten Thormann, Senior Vice President, LEO Pharma
Shire enables people with life-altering conditions to lead better lives. Shire focuses on developing and delivering innovative medicines for patients with rare diseases and other specialty conditions. This might be a therapy to treat an extremely rare and life-threatening disease such as Hunter syndrome or Fabry disease, or a medicine for a specialist condition such as ADHD or ulcerative colitis.
“Our collaboration has exceeded our expectations in delivering highly differentiated antibody programs within our therapeutic focus. The time is right to commit more significantly to the company through a longer term investment in its unique, world class technologies.”
Dr. Philip J.Vickers, Global Head of Research and Development
Staten Biotechnology aims to develop novel and innovative strategies for the prevention of cardiovascular events, the largest unmet medical need in dyslipidemia. Dyslipidemia is an abnormal amount of lipids or fat in the blood, namely triglycerides, cholesterol, or fat phospholipids. In developed countries most dyslipidemias are hyperlipidemia, i.e. elevation of lipids in the blood, and can be caused by genetic factors, diet, and lifestyle.
Staten is developing a human monoclonal antibody with a unique approach towards neutralizing apoC3 - a key molecule in dyslipidemia management - which reduces triglyceride levels and increases removal of atherogenic lipoprotein remnant particles. With this monoclonal antibody Staten is leading the next step in dyslipidemia management.